Pharmaceutical Industry Financial Analysis 2011 - Pfizer, Gsk, Takeda, Astrazeneca
Autor: aqilishtiaq • January 11, 2012 • Case Study • 1,205 Words (5 Pages) • 2,562 Views
Our team has conducted financial analysis on 4 global pharmaceutical companies: Pfizer from U.S.,
GlaxoSmithKline („GSK‟) from UK, Takeda Pharmaceutical from Japan („Takeda‟) and AstraZeneca Plc also
from U.S. Together these 4 pharmaceutical products and services providers had sales of over $160 Billion in
2010. These established and mature markets of U.S., UK and Japan combined represent approximately 30% of
the global demand for pharmaceuticals. According to a latest research by RNCOS Industry Research Solutions
called “Global Pharmaceutical Market Forecast to 2012”, the industry is estimated to grow at 6.5% between
2011 through 2013. This is coming after a 2 year industry wide slow growth period (2008 to 2009). It is also
important to note that we have considered and presented the combined financial data of these 4 pharmaceuticals
as “Industry” for the various analysis and arguments throughout this paper.
Some Quick Facts:
Global pharmaceutical players having worldwide consumer base.
Above 4 pharmaceuticals have approximately 20% of the global market share as per 2010 global market
size of around $800 Billion.
The 4 employ over 280,000 personnel worldwide.
FINANCIAL ANALYSIS (based on ANNUAL REPORTS of 2008 - 2010):-
The following are the 3 most important factors affecting the profitability of these firms
Firstly, we have analyzed each pharmaceutical‟s margin contribution: Cost of Goods Sold (COGS), Research &
Development (R&D), Supplies & Administration (SG&A) and Profit margin (see below graphs). We were able
to conclude both R&D and SG&A as significantly greater expenses even higher than that of COGS, which
normally constitutes a larger portion of total expense breakup in other industries.
From the below graphical layout, one can determine the individual firm R&D expense is between the range of
29% (for Pfizer) to upwards of 46% (for GSK). Though the firms‟ actual production cost is kept low but their
R&D portion is significantly higher.
...